Modulation of novel cardiorenal and inflammatory biomarkers by intravenous nitroglycerin and nesiritide in acute decompensated heart failure an exploratory study

Circulation: Heart Failure

Volumn 4, Issue 4, 2011, Pages 450-455

  Chow, Sheryl L ^a,b,d   O'Barr, Stephen A ^a   Peng, Jessica ^a,b   Chew, Eric ^b   Pak, Firooz ^b   Quist, Ryan ^a   Patel, Paryus ^b   Patterson, J Herbert ^c   Heywood, J Thomas ^d  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b Centinela Freeman Regional Medical Center   (United States)

^c University of North Carolina   (United States)

^d SCRIPPS CLINIC   (United States)

Author keywords

Biomarkers; Heart failure; Inflammation; Natriuretic peptides; Nitroglycerin; Renal failure

Indexed keywords

C REACTIVE PROTEIN; CYSTATIN C; GLYCERYL TRINITRATE; INTERLEUKIN 6; NESIRITIDE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; NATRIURETIC FACTOR; VASODILATOR AGENT;

ACUTE HEART FAILURE; AGED; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG INFUSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SENSITIVITY ANALYSIS; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; GLOMERULUS FILTRATION RATE; HEART FAILURE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CYSTATIN C; FEMALE; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; INFUSIONS, INTRAVENOUS; INTERLEUKIN-6; KIDNEY; MALE; MIDDLE AGED; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; NITROGLYCERIN; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TRANSFORMING GROWTH FACTOR BETA1; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VASODILATOR AGENTS;

EID: 80052798006     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.110.958066     Document Type: Article

References (37)

1. van der Putten K, Braam B, Jie KE, Gaillard CA. Mechanisms of disease: erythropoietin resistance in patients with both heart and kidney failure. Nat Clin Pract Nephrol. 2008;4:47-57. (Pubitemid 350308210)
2. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52:1527-1539.
3. Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008;358: 2148-2159.
4. Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, Sawyer DB, Levy D, Wilson PW, D'Agostino RB. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation. 2003;107: 1486-1491. (Pubitemid 36378485)
5. Miettinen KH, Lassus J, Harjola VP, Siirila-Waris K, Melin J, Punnonen KR, Nieminen MS, Laakso M, Peuhkurinen KJ. Prognostic role of proand anti-inflammatory cytokines and their polymorphisms in acute decompensated heart failure. Eur J Heart Fail. 2008;10:396-403.
6. Heart Failure Society of America. HFSA 2006 comprehensive heart failure practice guideline. J Card Fail. 2006;12:e1-e2.
7. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW. Focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009;119:1977-2016.
8. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, Vahanian A, Camm J, De Caterina R, Dean V, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Auricchio A, Bax J, Bohm M, Corra U, della Bella P, Elliott PM, Follath F, Gheorghiade M, Hasin Y, Hernborg A, Jaarsma T, Komajda M, Kornowski R, Piepoli M, Prendergast B, Tavazzi L, Vachiery JL, Verheugt FW, Zannad F. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology: developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008;10:933-989.
9. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487-1491.. (Pubitemid 40470642)
10. Chow SL, Peng JT, Okamoto MP, Heywood JT. Effect of nesiritide infusion duration on renal function in acutely decompensated heart failure patients. Ann Pharmacother. 2007;41:556-561. (Pubitemid 46625477)
11. Witteles RM, Kao D, Christopherson D, Matsuda K, Vagelos RH, Schreiber D, Fowler MB. Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol. 2007;50:1835-1840. (Pubitemid 350007964)
12. Chow SL, O'Barr SA, Peng J, Chew E, Pak F, Quist R, Patel P, Patterson JH, Heywood JT. Renal function and neurohormones following intravenous infusions of nitroglycerin versus nesiritide in patients with acute decompensated heart failure. J Card Fail. 2010;17:181-187.
13. Hojs R, Bevc S, Ekart R, Gorenjak M, Puklavec L. Serum cystatin c as an endogenous marker of renal function in patients with mild to moderate impairment of kidney function. Nephrol Dial Transplant. 2006;21: 1855-1862. (Pubitemid 43985713)
14. Erdfelder E, Faul F, Buchner A. Gpower: a general power analysis program. Behav Res Methods Instrum Comput. 1996;28:1-11. (Pubitemid 126416697)
15. Naruse H, Ishii J, Kawai T, Hattori K, Ishikawa M, Okumura M, Kan S, Nakano T, Matsui S, Nomura M, Hishida H, Ozaki Y. Cystatin c in acute heart failure without advanced renal impairment. Am J Med. 2009;122: 566-573.
16. Lassus J, Harjola VP, Sund R, Siirila-Waris K, Melin J, Peuhkurinen K, Pulkki K, Nieminen MS. Prognostic value of cystatin c in acute heart failure in relation to other markers of renal function and nt-proBNP. Eur Heart J. 2007;28:1841-1847. (Pubitemid 47236639)
17. Laterza OF, Price CP, Scott MG. Cystatin c: an improved estimator of glomerular filtration rate? Clin Chem. 2002;48:699-707. (Pubitemid 34439101)
18. Hoek FJ, Kemperman FA, Krediet RT. A comparison between cystatin c, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant. 2003;18: 2024-2031. (Pubitemid 37220307)
19. Kazama JJ, Kutsuwada K, Ataka K, Maruyama H, Gejyo F. Serum cystatin c reliably detects renal dysfunction in patients with various renal diseases. Nephron. 2002;91:13-20. (Pubitemid 34522827)
20. Sato Y, Takatsu Y, Kataoka K, Yamada T, Taniguchi R, Sasayama S, Matsumori A. Serial circulating concentrations of c-reactive protein, interleukin (IL)-4, and IL-6 in patients with acute left heart decompensation. Clin Cardiol. 1999;22:811-813.
21. Suzuki H, Sato R, Sato T, Shoji M, Iso Y, Kondo T, Shibata M, Koba S, Katagiri T. Time-course of changes in the levels of interleukin 6 in acutely decompensated heart failure. Int J Cardiol. 2005;100:415-420.
22. Peschel T, Schonauer M, Thiele H, Anker SD, Schuler G, Niebauer J. Invasive assessment of bacterial endotoxin and inflammatory cytokines in patients with acute heart failure. Eur J Heart Fail. 2003;5:609-614. (Pubitemid 38043965)
23. Chin BS, Conway DS, Chung NA, Blann AD, Gibbs CR, Lip GY. Interleukin-6, tissue factor and von Willebrand factor in acute decompensated heart failure: relationship to treatment and prognosis. Blood Coagul Fibrinolysis. 2003;14:515-521. (Pubitemid 37083165)
24. Milani RV, Mehra MR, Endres S, Eigler A, Cooper ES, Lavie CJ Jr, Ventura HO. The clinical relevance of circulating tumor necrosis factor-alpha in acute decompensated chronic heart failure without cachexia. Chest. 1996;110:992-995. (Pubitemid 26347615)
25. Chin BS, Blann AD, Gibbs CR, Chung NA, Conway DG, Lip GY. Prognostic value of interleukin-6, plasma viscosity, fibrinogen, von Willebrand factor, tissue factor and vascular endothelial growth factor levels in congestive heart failure. Eur J Clin Invest. 2003;33:941-948. (Pubitemid 37421591)
26. Gwechenberger M, Mendoza LH, Youker KA, Frangogiannis NG, Smith CW, Michael LH, Entman ML. Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions. Circulation. 1999;99:546-551. (Pubitemid 29061871)
27. Yamauchi-Takihara K, Ihara Y, Ogata A, Yoshizaki K, Azuma J, Kishimoto T. Hypoxic stress induces cardiac myocyte-derived interleukin-6. Circulation. 1995;91:1520-1524.
28. Dupuis J, Lalonde G, Lemieux R, Rouleau JL. Tolerance to intravenous nitroglycerin in patients with congestive heart failure: role of increased intravascular volume, neurohumoral activation and lack of prevention with n-acetylcysteine. J Am Coll Cardiol. 1990;16:923-931. (Pubitemid 20353414)
29. Abraham WT, Lowes BD, Ferguson DA, Odom J, Kim JK, Robertson AD, Bristow MR, Schrier RW. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail. 1998;4:37-44. (Pubitemid 28252539)
30. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1231-1239.
31. Kapoun AM, Liang F, O'Young G, Damm DL, Quon D, White RT, Munson K, Lam A, Schreiner GF, Protter AA. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res. 2004;94:453-461. (Pubitemid 38326280)
32. Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J. 1994;72:561-566.
33. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323:236-241. (Pubitemid 20225044)
34. Wiedermann CJ, Beimpold H, Herold M, Knapp E, Braunsteiner H. Increased levels of serum neopterin and decreased production of neutrophil superoxide anions in chronic heart failure with elevated levels of tumor necrosis factor-alpha. J Am Coll Cardiol. 1993;22:1897-1901. (Pubitemid 23359650)
35. Matsumura T, Tsushima K, Ohtaki E, Misu K, Tohbaru T, Asano R, Nagayama M, Kitahara K, Umemura J, Sumiyoshi T, Hosoda S. Effects of carvedilol on plasma levels of interleukin-6 and tumor necrosis factor-alpha in nine patients with dilated cardiomyopathy. J Cardiol. 2002;39:253-257. (Pubitemid 40745785)
36. Sola S, Mir MQ, Lerakis S, Tandon N, Khan BV. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol. 2006;47:332-337. (Pubitemid 43063250)
37. Bleske BE, Nicklas JM, Bard RL, Brook RD, Gurbel PA, Bliden KP, Rajagopalan S, Pitt B. Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-COA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level. J Am Coll Cardiol. 2006;47:338-341. (Pubitemid 43063251)